Julian F. R. Paton, Benedito H. Machado, Davi J. A. Moraes, Daniel B. Zoccal, Ana P. Abdala, Jeffrey C. Smith, Vagner R. Antunes, David Murphy, Mathias Dutschmann, Rishi R. Dhingra, Robin McAllen, Anthony E. Pickering, Richard J. A. Wilson, Trevor A. Day, Nicole O. Barioni, Andrew M. Allen, Clément Menuet, Joseph Donnelly, Igor Felippe, Walter M. St‐John, Department of Economics, University of Wisconsin, UCL, Institute of Neurology [London], Centre de recherche en neurobiologie - neurophysiologie de Marseille (CRN2M), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Mount Royal/Mount Royal University [Calgary, AB, Canada] (MRU), J. Craig Venter Institute [La Jolla, USA] (JCVI), University of California [San Diego] (UC San Diego), University of California (UC), Institut de Neurobiologie de la Méditerranée [Aix-Marseille Université] (INMED - INSERM U1249), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and A.P.A. -R01 AT008632 -CRCNS. A.M.A. -Australian Research Council (DP170104582) and Australian National Health and Medical Research Council (APP1156727). V.R.A. Sao Paulo Research Foundation (FAPESP 2019/19894-8) and National Council for Development of Science and Technology (CNPq -Research Fellow: no. 304970/2017-4). R.R.D. -National Institutes of Health (U01 EB021960). J.D. -Clinical Fellowship from the Neurological Foundation of New Zealand. I.S.A.F. -University of Auckland PhD scholarship. B.H.M. Sao Paulo Research Foundation (FAPESP-2018/15957-2) and the National Council for Development of Science and Technology (CNPq-309338/2020-4). C.M. -Agence Nationale de la Recherche (ANR-21-CE14-0009-01). D.J.A.M. -FAPESP (2019/11863-6 and 2021/06886-7) and CNPq (437375/2018-8 and 313719/2020-9). J.F.R.P. -Health Research Council of New Zealand (19/687) and the Sidney Taylor Trust. A.E.P. was funded by a Wellcome Trust Clinical research fellowship. J.C.S. -Intramural Research Program of the NIH, NINDS. T.A.D. -Natural Sciences and Engineering Research Council of Canada Discovery grants (NSERC RGPIN-2016-04915). R.J.A. W. -Canada Institute of Health Research (CIHR201603PJT/366421). N.O.B. -SIDS Calgary Society.
Twenty-five years ago, a new physiological preparation called the working heart–brainstem preparation (WHBP) was introduced with the claim it would provide a new platform allowing studies not possible before in cardiovascular, neuroendocrine, autonomic and respiratory research. Herein, we review some of the progress made with the WHBP, some advantages and disadvantages along with potential future applications, and provide photographs and technical drawings of all the customised equipment used for the preparation. Using mice or rats, the WHBP is an in situ experimental model that is perfused via an extracorporeal circuit benefitting from unprecedented surgical access, mechanical stability of the brain for whole cell recording and an uncompromised use of pharmacological agents akin to in vitro approaches. The preparation has revealed novel mechanistic insights into, for example, the generation of distinct respiratory rhythms, the neurogenesis of sympathetic activity, coupling between respiration and the heart and circulation, hypothalamic and spinal control mechanisms, and peripheral and central chemoreceptor mechanisms. Insights have been gleaned into diseases such as hypertension, heart failure and sleep apnoea. Findings from the in situ preparation have been ratified in conscious in vivo animals and when tested have translated to humans. We conclude by discussing potential future applications of the WHBP including two-photon imaging of peripheral and central nervous systems and adoption of pharmacogenetic tools that will improve our understanding of physiological mechanisms and reveal novel mechanisms that may guide new treatment strategies for cardiorespiratory diseases.